Literature & Publications

Cortexyme Publications

Gingipains Identified in Alzheimer’s Disease Brains Differentially Fragment ApoE Proteins. 2021.
Alzheimer’s Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains. Journal of Alzheimer’s Disease 2020.
Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. Pharmacology Research and Perspectives, 2020.
Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science Advances, 2019.

Cortexyme Posters & Presentations

Video: Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease. CTAD 2021.
Presentation: Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease. CTAD 2021.
Presentation: GAIN Trial Top-Line Results Overview. October 2021.
PRESENTATION: Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial. Biomarkers for Alzheimer’s Disease Summit 2021.
VIDEO: USE OF NOVEL BIOMARKERS OF P. GINGIVALIS INFECTION & NEUROINFLAMMATION IN THE GAIN TRIAL. BIOMARKERS FOR ALZHEIMER’S DISEASE SUMMIT 2021.
VIDEO: AAIC 2021 Cortexyme Symposium: Getting to the Root Cause of Alzheimer’s Disease:  An Innovative, Upstream Approach for Disease Modification
PRESENTATION: AAIC 2021 Cortexyme Symposium: Getting to the Root Cause of Alzheimer’s Disease:  An Innovative, Upstream Approach for Disease Modification
Increased Levels of Phospho-Tau217 in Neuron Cultures and CVN Mice Infected with Porphyromonas Gingivalis. AAIC 2021.
An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. AAIC 2021.
Gingipain Inhibitors Penetrate And Inhibit Gingipains In Porphyromonas gingivalis Biofilms. IADR 2021.
Novel lysine-gingipain inhibitor atuzaginstat (COR388) is efficacious in a mouse model of periodontal disease. IADR 2021.
Presentation: An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. ASCP 2021.
Poster: An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. ASCP 2021.
Ultrastructural localization of Porphyromonas gingivalis RgpB virulence factor in the middle temporal gyrus (MTG) of the Alzheimer’s disease human brain. AAT-AD/PD 2021.
PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat. SITC 2020.
Comprehensive Alzheimer’s pathology is induced by P. gingivalis infection: COR388 and other gingipain inhibitors protect against synaptic loss. AAIC 2020.
Targeting Porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease. AAIC 2020.
COR388, a novel gingipain inhibitor, decreases fragmentation of ApoE in the central nervous system of Alzheimer’s disease patients. AAIC 2020.
Novel gingipain inhibitors are efficacious in treatment of periodontal disease. IADR 2020.
Intracellular Porphyromonas gingivalis in Neuron-astrocyte-microglia Co-cultures Results in Alzheimer’s disease-like Phenotype. AAT-AD/PD 2020.
Initiation of the Phase 2/3 GAIN trial of COR388, a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease based on Phase 1 a/b safety, PK, biomarker, and efficacy data. AAIC 2019.
A Randomized, Placebo-Controlled, Repeat Dose Phase 1 Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer’s Disease. CTAD 2018.

Alzheimer’s Disease

Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One 2018.
Periodontitis induced by bacterial infection exacerbates features of Alzheimer’s disease in transgenic mice. NPJ Aging Mech Dis 2017.
Active Invasion of Porphyromonas gingivalis and Infection-Induced Complement Activation in ApoE-/- Mice Brains. Journal of Alzheimer’s Disease 2014.
Alzheimer’s Disease-Like Pathology Triggered by Porphyromonas gingivalis in Wild Type Rats Is Serotype Dependent. Frontiers in Immunology 2020.
Tran et al. Effects of Porphyromonas gingivalis and Its Underlying Mechanisms on Alzheimer-Like Tau Hyperphosphorylation in Sprague-Dawley Rats. Journal of Molecular Neuroscience 2020.
Periodontitis Deteriorates Cognitive Function and Impairs Neurons and Glia in a Mouse Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease 2021.
Tooth loss, dementia and neuropathology in the Nun Study. Journal Am Dent Assoc 2007.
Potentially modifiable risk factors for dementia in identical twins. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 2006.
Tooth loss and periodontal disease predict poor cognitive function in older men. J Am Geriatric Society 2010.
Determining the Presence of Periodontopathic Virulence Factors in Short-Term Postmortem Alzheimer’s Disease Brain Tissue. Journal of Alzheimer’s Disease 2013.
Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiology of Aging 2015.
Periodontitis and Cognitive Decline in Alzheimer’s Disease. PLoS One 2016.
Porphyromonas gingivalis is the most abundant species detected in coronary and femoral arteries. J Oral Microbiology 2017.
Alzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence. Journal of Alzheimer’s Disease 2018.
The Alzheimer’s Disease-Associated Amyloid b-Protein Is an Antimicrobial Peptide. PLoS One 2010.
Amyloid-β Peptide Protects Against Microbial Infection In Mouse and Worm Models of Alzheimer’s Disease. Science Translational Medicine 2016.

Periodontal Disease

The Role of Gingipains in the Pathogenesis of Periodontal Disease. American Academy of Periodontology 2003.
The lysine-specific gingipain of Porphyromonas gingivalis: Importance to pathogenicity and potential strategies for inhibition. Advances in Experimental Medicine and Biology 2011.
Structure of the lysine specific protease Kgp from Porphyromonas gingivalis, a target for improved oral health. Protein Sciences 2015.

Parkinson’s Disease

Braak et al. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission 2003
Is Porphyromonas gingivalis involved in Parkinson’s disease? European Journal of Clinical Microbiology & Infectious Diseases 2020
Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. Journal of Neuroinflammation 2020.
Parkinson’s Disease: A Systemic Inflammatory Disease Accompanied by Bacterial Inflammagens. Frontiers in Aging Neuroscience. 2019
Oral Health of Parkinson’s Disease Patients: A Case-Control Study. Parkinson’s disease 2018
Periodontal inflammatory disease is associated with the risk of Parkinson’s disease: a population-based retrospective matched-cohort study. PeerJ. 2017.
Association of Tooth Loss with New-Onset Parkinson’s Disease: A Nationwide Population-Based Cohort Study. Parkinson’s Disease. 2020.
Dental Scaling Decreases the Risk of Parkinson’s Disease: A Nationwide Population-Based Nested Case-Control Study. International Journal of Environmental Research and Public Health. 2018.
The potential impact of periodontitis on the pathogenesis of Parkinson’s disease and cognitive deficits
Immunogenetics of Parkinson’s disease
Functional characterization of alpha-synuclein protein with antimicrobial activity. Biochemical and Biophysical Research Communications. 2016.
Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease. Frontiers in Neuroscience. 2019.
Gastrointestinal Immunity and Alpha-Synuclein. Journal of Parkinson’s diseases. 2019.
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. Journal of Neural Transmission. 2019.

Oncology

Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infectious Agents and Cancer. 2016
Possible role of Porphyromonas gingivalis in orodigestive cancers. Journal of Oral Microbiology 2019.
Porphyromonas gingivalis promotes progression of esophageal squamous cell cancer via TGFβ-dependent Smad/YAP/TAZ signaling
Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review

P. gingivalis and Other Indications

P. gingivalis in Periodontal Disease and Atherosclerosis – Scenes of Action for Antimicrobial Peptides and Complement
Ingestion of Porphyromonas gingivalis exacerbates colitis via intestinal epithelial barrier disruption in mice
Periodontal infection with Porphyromonas gingivalis induces preterm birth and lower birth weight in rats
Dental Infection of Porphyromonas gingivalis Induces Preterm Birth in Mice
Furusho et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice